Stem cell therapy for autoimmune disease

Stem cell therapy for autoimmune disease uses living cells — mesenchymal stromal cells (MSC) or regulatory T cells (Treg) — to re-tolerise rather than suppress the immune system, addressing lupus, Crohn’s, arthritis, GVHD and aplastic anaemia. Mesoblast’s Ryoncil (remestemcel-L) saw the FDA accept its Biologics License Application for paediatric steroid-refractory acute graft-versus-host disease; TiGenix (a Takeda company) provides Alofisel (darvadstrocel) for Crohn’s disease perianal fistulas; Cellenkos received FDA clearance for a Phase 2 trial of CK0801 (allogeneic cord-blood Treg) in aplastic anaemia; Sonoma Biotherapeutics is advancing an engineered-Treg pipeline in autoimmune disease; and GentiBio presented preclinical data for GNTI-122, an autologous antigen-specific engineered Treg.

The key directions of stem cell therapy for autoimmune disease are:

1. Mesenchymal stromal cell therapy (MSC): allogeneic MSC immunomodulation for inflammatory disease — Mesoblast (remestemcel-L/Ryoncil, steroid-refractory acute GVHD), TiGenix (darvadstrocel/Alofisel, Crohn’s perianal fistula).
2. Regulatory T-cell therapy (Treg): polyclonal or antigen-specific Treg infusion to restore tolerance — Cellenkos (CK0801 cord-blood Treg, aplastic anaemia), Sonoma Biotherapeutics (engineered Treg), GentiBio (GNTI-122 antigen-specific Treg).
3. Haematopoietic stem-cell reset (HSCT): autologous HSCT for severe refractory autoimmune disease (lupus, MS), a clinical-procedure rather than product-led approach.
4. Allogeneic off-the-shelf manufacturing (Allogeneic Manufacturing): donor-derived MSC and Treg banking that supports repeat-dose, inventory-managed cell therapy.

Sectoral value chain#

[donor MSC / cord-blood Treg / patient Treg] ──> [ex vivo activation, engineering & expansion] ──> [cryopreserved cell product]
                                              │
                                     (conditioning as needed)
                                              │
                                              ▼
[immune tolerance restored] <─── [cell infusion + immune monitoring] <─────┘

Value chain levels#

Cross-cutting technologies of the sector:

• MSC immunomodulation (MSC): allogeneic MSC suppress inflammation via IDO, PGE2 and T-cell modulation, enabling off-the-shelf use across HLA barriers (Mesoblast, TiGenix).
• Treg stability and specificity (Treg): maintaining FOXP3 expression and engineering antigen-specific TCRs so the infused Treg homes to the diseased tissue (Cellenkos, Sonoma, GentiBio).
• Allogeneic off-the-shelf banking (Allogeneic Manufacturing): donor-derived MSC/Treg banked as inventory distinguishes this class from autologous cell therapy.

The stack pairs MSC or Treg cell sourcing with ex vivo expansion (and Treg engineering), allogeneic GMP banking, and immune-tolerance monitoring.

1. Mesenchymal stromal cell therapy (MSC):
   • Mesoblast’s Ryoncil (remestemcel-L) had its BLA accepted for paediatric steroid-refractory acute GVHD, and TiGenix’s Alofisel (darvadstrocel) is EU-approved for Crohn’s perianal fistula — the two lead commercial autoimmune/inflammatory MSC assets.
   • Allogeneic MSC act via IDO/PGE2 immunomodulation across HLA barriers, enabling off-the-shelf use.
2. Regulatory T-cell therapy (Treg):
   • Cellenkos’s CK0801 (allogeneic cord-blood Treg) entered Phase 2 in aplastic anaemia; Sonoma Biotherapeutics is clinical-stage in engineered Treg for autoimmune disease, and GentiBio presented preclinical data for GNTI-122, an antigen-specific engineered Treg.
   • Maintaining FOXP3 stability and engineering tissue-specific TCRs is what converts polyclonal Treg into disease-targeted tolerance therapy.
3. Allogeneic manufacturing (Allogeneic Manufacturing):
   • Donor-derived MSC and cord-blood Treg are banked as inventory, a structural shift from autologous cell therapy toward repeat-dose off-the-shelf cell drugs.